Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis

Immunobiology

Volumn 220, Issue 6, 2015, Pages 817-822

  Gui, Huan ^a,b,c   Liu, Xia ^b   Liu, Li Rong ^a   Su, Ding Feng ^b   Dai, Sheng Ming ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cannabinoid receptor 2; Collagen induced arthritis; Rheumatoid arthritis

Indexed keywords

4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ANANDAMIDE; AUTOANTIBODY; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; CANNABINOID; COLLAGEN; COMPLEMENT COMPONENT C2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE MINERALIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIGITAL RADIOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; IMMUNOMODULATION; IN VITRO STUDY; INCIDENCE; JOINT DESTRUCTION; JOINT SWELLING; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVIOCYTE; SYNOVITIS; SYNOVIUM; AGONISTS; ANIMAL; ARTHRITIS, EXPERIMENTAL; BIOSYNTHESIS; BLOOD; DISEASE MODEL; IMMUNOLOGY; JOINT; KNOCKOUT MOUSE; MACROPHAGE; MALE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; CANNABINOIDS; COLLAGEN; COMPLEMENT C2; DISEASE MODELS, ANIMAL; INTERLEUKIN-6; JOINTS; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; RECEPTOR, CANNABINOID, CB2; SEVERITY OF ILLNESS INDEX; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA; X-RAY MICROTOMOGRAPHY;

EID: 84988264024     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.12.012     Document Type: Article

References (39)

1. Bartok B., Firestein G.S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 2010, 233(1):233-255.
2. Buch M.H., Emery P. New therapies in the management of rheumatoid arthritis. Curr. Opin. Rheumatol. 2011, 23(3):245-251.
3. Chiurchiu V., Lanuti M., Catanzaro G., Fezza F., Rapino C., Maccarrone M. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis 2014, 233(1):55-63.
4. Dajani E.Z., Larsen K.R., Taylor J., et al. 1',1'-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. J. Pharmacol. Exp. Ther. 1999, 291(1):31-38.
5. Fukuda S., Kohsaka H., Takayasu A., et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet. Disord. 2014, 15:275.
6. Guabiraba R., Russo R.C., Coelho A.M., et al. Blockade of cannabinoid receptors reduces inflammation, leukocyte accumulation and neovascularization in a model of sponge-induced inflammatory angiogenesis. Inflamm. Res. 2013, 62(8):811-821.
7. Gui H., Sun Y., Luo Z.M., Su D.F., Dai S.M., Liu X. Cannabinoid receptor 2 protects against acute experimental sepsis in mice. Mediators Inflamm. 2013, 2013:741303.
8. Gui H., Liu X., Wang Z.W., He D.Y., Su D.F., Dai S.M. Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis. Rheumatology 2014, 53(5):802-809.
9. Guillot A., Hamdaoui N., Bizy A., et al. Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology 2014, 59(1):296-306.
10. Hanus L., Breuer A., Tchilibon S., et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(25):14228-14233.
11. Howlett A.C., Barth F., Bonner T.I., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54(2):161-202.
12. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005, 5(5):400-411.
13. Kong W., Li H., Tuma R.F., Ganea D. Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS. Cell. Immunol. 2014, 287(1):1-17.
14. Lee S.F., Newton C., Widen R., Friedman H., Klein T.W. Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur. J. Pharmacol. 2001, 423(2-3):235-241.
15. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346(6284):561-564.
16. Mbvundula E.C., Bunning R.A., Rainsford K.D. Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro. J. Pharm. Pharmacol. 2006, 58(3):351-358.
17. McInnes I.B., O'Dell J.R. State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69(11):1898-1906.
18. Michler T., Storr M., Kramer J., et al. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304(2):G181-G192.
19. Miller L.K., Devi L.A. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol. Rev. 2011, 63(3):461-470.
20. Mullazehi M., Mathsson L., Lampa J., Ronnelid J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann. Rheum. Dis. 2007, 66(4):537-541.
21. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365(6441):61-65.
22. Nandakumar K.S., Andren M., Martinsson P., et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB. Eur. J. Immunol. 2003, 33(8):2269-2277.
23. Ofek O., Karsak M., Leclerc N., et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(3):696-701.
24. Qin Y.H., Dai S.M., Tang G.S., et al. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J. Immunol. 2009, 183(10):6244-6250.
25. Ramirez S.H., Hasko J., Skuba A., et al. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 2012, 32(12):4004-4016.
26. Ray K. Rheumatoid arthritis: clue to role of cannabinoid receptors in RA. Nat. Rev. Rheumatol. 2014, 10(3):128.
27. Rhee M.H., Vogel Z., Barg J., et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J. Med. Chem. 1997, 40(20):3228-3233.
28. Ribeiro R., Yu F., Wen J., Vana A., Zhang Y. Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis. Neuroscience 2013, 254:427-442.
29. Richardson D., Pearson R.G., Kurian N., et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 2008, 10(2):R43.
30. Rom S., Zuluaga-Ramirez V., Dykstra H., Reichenbach N.L., Pacher P., Persidsky Y. Selective activation of cannabinoid receptor 2 in leukocytes suppresses their engagement of the brain endothelium and protects the blood-brain barrier. Am. J. Pathol. 2013, 183(5):1548-1558.
31. Rossi F., Bernardo M.E., Bellini G., et al. The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties. PLOS ONE 2013, 8(11):e80022.
32. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376(9746):1094-1108.
33. Singh U.P., Singh N.P., Singh B., Price R.L., Nagarkatti M., Nagarkatti P.S. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol. Appl. Pharmacol. 2012, 258(2):256-267.
34. Sophocleous A., Landao-Bassonga E., Van't Hof R.J., Idris A.I., Ralston S.H. The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology 2011, 152(6):2141-2149.
35. Storr M.A., Keenan C.M., Zhang H., Patel K.D., Makriyannis A., Sharkey K.A. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm. Bowel Dis. 2009, 15(11):1678-1685.
36. Toguri J.T., Lehmann C., Laprairie R.B., et al. Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis. Br. J. Pharmacol. 2014, 171(6):1448-1461.
37. Wang Z.Y., Wang P., Bjorling D.E. Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitis. J. Urol. 2014, 191(4):1153-1158.
38. Zoratti C., Kipmen-Korgun D., Osibow K., Malli R., Graier W.F. Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br. J. Pharmacol. 2003, 140(8):1351-1362.
39. Zurier R.B., Rossetti R.G., Lane J.H., Goldberg J.M., Hunter S.A., Burstein S.H. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. 1998, 41(1):163-170.